Impact of Field Isolate Identified Nonsynonymous Single Nucleotide Polymorphisms on Plasmodium falciparum Equilibrative Nucleoside Transporter 1 Inhibitor Efficacy
Authors:
- 13 January 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (2) , 205-214
Abstract
Plasmodium falciparum causes the most severe form of malaria and causes approximately 500,000 deaths per year. P. falciparum parasites resistant to current anti-malarial treatments are spreading. Therefore, it is imperative to develop new anti-malarial drugs. Malaria parasites are purine auxotrophic. They rely on purine import from the host erythrocyte via Equilibrative Nucleoside Transporters (ENTs). Recently, inhibitors of the P. falciparum ENT1 (PfENT1) that inhibit proliferation of malaria parasites in culture have been identified as promising starting points for antimalarial drug development. Genome sequencing of P. falciparum field isolates has identified non-synonymous single nucleotide polymorphisms (SNPs) in the gene encoding PfENT1. Here we evaluate the impact of these PfENT1 SNPs on purine substrate affinity and inhibitor efficacy. We expressed each PfENT1-SNP in Saccharomyces cerevisiae. Using PfENT1-SNP-expressing yeast, we characterized the PfENT1 purine substrate affinity using radiolabeled substrate uptake inhibition experiments. Four of the 13 SNPs altered affinity for one or more purines by up to 7-fold. Three of the SNPs reduced the potency of a subset of the inhibitors by up to 7-fold. One SNP, Q284E, reduced the potency of all six inhibitor chemotypes. We tested drug efficacy in available parasite strains containing PfENT1 SNPs. While PfENT1-SNP-expressing yeast had decreased sensitivity to PfENT1 inhibitors, parasite strains containing SNPs showed similar or more potent inhibition of proliferation with all PfENT1 inhibitors. Thus, parasite strains bearing PfENT1 SNPs are not resistant to these PfENT1 inhibitors. This supports PfENT1 as a promising target for further development of novel antimalarial drugs.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (F31-AI136488, RO1-AI116665)
This publication has 30 references indexed in Scilit:
- Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine SensitivityThe Journal of Infectious Diseases, 2017
- Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of VietnamMalaria Journal, 2017
- Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical AssessmentAntimicrobial Agents and Chemotherapy, 2015
- Genetic architecture of artemisinin-resistant Plasmodium falciparumNature Genetics, 2015
- Purine import into malaria parasites as a target for antimalarial drug developmentAnnals of the New York Academy of Sciences, 2014
- Spread of Artemisinin Resistance in Plasmodium falciparum MalariaNew England Journal of Medicine, 2014
- Plasmodium falciparum Parasites Are Killed by a Transition State Analogue of Purine Nucleoside Phosphorylase in a Primate Animal ModelPLOS ONE, 2011
- Genetic evidence for the essential role of PfNT1 in the transport and utilization of xanthine, guanine, guanosine and adenine by Plasmodium falciparumMolecular and Biochemical Parasitology, 2008
- Purine Salvage Pathways in the Intraerythrocytic Malaria Parasite Plasmodium falciparumEukaryotic Cell, 2008
- Mutations in Plasmodium falciparum Cytochrome b That Are Associated with Atovaquone Resistance Are Located at a Putative Drug-Binding SiteAntimicrobial Agents and Chemotherapy, 2000